1/8/2024 0 Comments The paina 95.9“I love serving the community and helping out,” he said. He’s is also considering running for office. Instead of letting it keep her down she created something that has now reached over 70,000 students,” Tulba said. “She (Mahealani Tulba) was bullied in school. Some of the money generated from his shows supports the foundation, and Tulba helps the foundation with skits that teach kids how to identify bullies and how to respond to bullying. Tulba said he’s not necessarily going to quit his current gigs on radio and touring Hawaii, but he’s focusing on a nationwide tour and on supporting his daughter Mahealani’s foundation, “Brave Hawaii,” which focuses on anti-bullying messaging to schools. The show marks a change in Tulba’s comedy career, which has been 27 years of regular shows throughout Hawaii and hosting the Augie Radio Show on 95.9 FM Da Pa’ina.ĭuring his time on the comedy scene, Tulba has also worked for marketing companies, for the mayor’s office on Hawaii Island and for Lt. “It’s a best of with some new stuff and I call it ‘Last Stand’ because I don’t know what’s next,” he said. The show is made up of new material, with some of his funniest bits sprinkled in - some of which was first aired out on the stage at the Waimea Theatre, where Tulba spends occasional weekends working on new bits. Now, Tulba’s getting ready to tour the country with his new show: “Augie T-Last Stand,” which he is filming as a special for Netflix and Amazon Prime. “I remember walking off stage saying ‘this sucks’ and Andy said ‘brah, you get ‘em, don’t quit’.” Nobody knew who I was and nobody laughed,” Tulba said. “I was this young comedian Andy Bumatai brought along. ![]() Demographic characteristic at study visit of patients with and without HZįigure 1.More than 20 years ago, Augie “T” Tulba took the stage at Vidinha Stadium as a young standup comedian, a gig that triggered a decades-long career and the release of nine comedy DVDs. HZ can be an early comorbidity in SLE, with 43.1% of cases occurring within 5 years of SLE diagnosis and 57% after 10 years of SLE diagnosis. The HZ prevalence of 30.8% was higher than previously published data in SLE. Seventy-two patients (56.7%) were on immunosuppressant (Azathioprine 31.5%, Mycophenolate mofetil 14.17%, Methotrexate 6.3% and cyclophosphamide 4.72%). ![]() Of those, 32 patients reported a mean prednisone dose of 23.3 mg/day (range, 3–60 mg). 1).Įighty patients (62.9%) reported taking prednisone at the time of HZ. The majority of the patients reported pain (95.9%) and 74.0% scored between 7-10 (Fig. HZ pain, itching or tingling in the rash area was reported in 96.7% of patients. 97.6% of HZ was confirmed by physician and 78% received anti-viral therapy. Most (78.8%) of those who developed HZ were not vaccinated prior to HZ. Mean SLE duration at first HZ was 9.6 ± 9.8 years. HZ occurred in the first 5 years post SLE diagnosis in 43.1% of patients, 18.1% reported HZ from 6-10 years and 38.2% reported HZ occurrence ≥10 years post SLE diagnosis. The demographic features of SLE patients with and without HZ are presented in Table 1. Of these 127 patients, 32 (25.2%) patients experienced recurrent HZ event, occurring within 12.2 ± 12.1 years from the 1 st HZ event. ![]() ![]() The prevalence of HZ was 127 (30.8%) at a mean age of 47.4 ± 13.7 years. Of 912 patients who visited the clinic within that period, 412 patients completed the survey. Analysis included descriptive statistics. All patients were evaluated according to a standard protocol which includes assessment of disease activity (SLE Disease Activity Index 2000 ). The survey was distributed to consecutive SLE patients attending the Lupus Clinic from January 2016 to April 2018. It includes different questions on patient’ demographics, the onset of HZ in relation the SLE onset, pain related to HZ, history of varicella zoster vaccine, anti-viral therapy for HZ, and several estimated risk factors for HZ. The objective of this study is to determine the prevalence and describe the characteristics of HZ in an SLE cohort.Ī patient questionnaire was developed to examine HZ in SLE patients. The higher prevalence of HZ in Systemic Lupus Erythematosus (SLE) patients is aggravated by the concomitant use of immunosuppressant and glucocorticoids (GCs). The prevalence of HZ is 3.6-19.9% in previously reported data. Herpes zoster (HZ) commonly observed in the elderly and in immune-compromised patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |